What is Enhanc3D Genomics?
Enhanc3D Genomics, a spinout from the Babraham Institute in Cambridge, UK, is at the forefront of regulatory genomics and chromosomal architecture. Founded by leading academic scientists, the company leverages its proprietary technology to advance understanding and applications within the life sciences. Supported by the StartCodon Accelerator and based at the Cambridge BioMedical Campus, Enhanc3D Genomics is positioned to make significant contributions to the field.
How much funding has Enhanc3D Genomics raised?
Enhanc3D Genomics has raised a total of $30.3M across 2 funding rounds:
Series A
$11.3M
Series A
$19M
Series A (2022): $11.3M with participation from BGF, Bioqube Ventures, and Parkwalk Advisors
Series A (2025): $19M led by Meltwind Advisory, Parkwalk Advisors, and BGF
Key Investors in Enhanc3D Genomics
Meltwind Advisory
Meltwind Advisory LLP provides guidance for early-stage healthcare and biotech companies, focusing on due diligence and portfolio management. Founded by Jonathan Milner, the firm specializes in investing in Series A and Series B life science tools and platform therapeutics.
Parkwalk Advisors
Parkwalk is a leading investor in university spinouts, focusing on deeptech innovations emerging from the UK's top universities. With over 15 years of experience, they bridge the gap between academic research and commercial success by providing funding, expertise, and networks to help these companies thrive.
BGF
BGF, headquartered in London, United Kingdom, is the most active and influential investor in small and mid-sized businesses in the UK. An established and independent company, it supports a range of growing companies - early stage, growth stage, and quoted - across every region and sector of the economy.
What's next for Enhanc3D Genomics?
The recent major enterprise-level funding and strategic investment signal a pivotal growth phase for Enhanc3D Genomics. This capital will likely fuel further research and development, expansion of its technological platform, and strategic partnerships. The company is poised to accelerate its mission of translating cutting-edge genomic insights into tangible advancements, solidifying its position as a key player in the biotech landscape.
See full Enhanc3D Genomics company page
